TRDA
Entrada Therapeutics, Inc.
$6.56
+0.25
(+3.96%)
Mkt Cap
254.66M
Volume
366,389
52W Range
4.93-16.45
Sector
Healthcare
Beta
-0.09
EPS (TTM)
-4.00
P/E Ratio
-2.96
Revenue (TTM)
5.74M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 25.42M | 210.78M | 129.01M | 0 | 0 | 0 | 0 |
| Net Income | (143.75M) | 65.63M | (6.68M) | (94.62M) | (51.16M) | (26.52M) | (4.65M) |
| EPS | -3.47 | 1.76 | -0.20 | -2.79 | -1.60 | -0.84 | -4.44 |
| Free Cash Flow | (129.55M) | (44.72M) | 134.19M | (96.67M) | (55.44M) | (27.89M) | (11.43M) |
| FCF / Share | -3.13 | -1.20 | 4.06 | -3.09 | -1.78 | -0.89 | -10.91 |
| Operating CF | (128.51M) | (41.56M) | 139.80M | (93.79M) | (50.86M) | (25.57M) | (10.80M) |
| Total Assets | 377.38M | 526.32M | 469.19M | 252.06M | 305.83M | 43.53M | 18.24M |
| Total Debt | 50.93M | 59.21M | 68.23M | 25.94M | 0 | 0 | 0 |
| Cash & Equiv | 90.39M | 101.21M | 67.60M | 45.16M | 291.06M | 39.05M | 16.84M |
| Book Value | 306.13M | 428.68M | 242.36M | 212.55M | 298.72M | (41.49M) | (15.52M) |
| Return on Equity | -0.47 | 0.15 | -0.03 | -0.45 | -0.17 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 875,000 | 1.30M | 1.61M | 1.95M | 20.56M | 37.40M | 19.57M | 94.69M | 59.12M | 41.85M | 43.73M | 18.17M |
| Net Income | (39.72M) | (39.16M) | (44.13M) | (43.10M) | (17.35M) | 1.13M | (14.03M) | 55.03M | 23.50M | (9.54M) | 35.46M | (25.93M) |
| EPS | -0.95 | -0.95 | -1.06 | -1.04 | -0.42 | 0.03 | -0.35 | 1.61 | 0.70 | -0.29 | 1.07 | -0.78 |
| Free Cash Flow | (41.74M) | (32.00M) | (28.14M) | (29.76M) | (39.65M) | (32.24M) | (24.91M) | 38.79M | (26.36M) | (4.99M) | (25.94M) | (36.61M) |
| FCF / Share | -1.00 | -0.77 | -0.68 | -0.72 | -0.97 | -0.79 | -0.61 | 1.13 | -0.79 | -0.15 | -0.78 | -1.10 |
| Operating CF | (41.70M) | (32.20M) | (28.31M) | (29.49M) | (38.51M) | (31.61M) | (24.27M) | 39.83M | (25.52M) | (4.01M) | (24.49M) | (35.09M) |
| Total Assets | 335.52M | 377.38M | 412.90M | 448.78M | 486.48M | 526.32M | 554.59M | 581.96M | 510.84M | 469.19M | 485.03M | 493.98M |
| Total Debt | 49.75M | 50.93M | 52.40M | 54.74M | 57.00M | 59.21M | 61.31M | 64.44M | 66.43M | 68.23M | 69.07M | 73.03M |
| Cash & Equiv | 76.44M | 90.39M | 93.29M | 72.48M | 67.84M | 101.21M | 78.05M | 185.25M | 68.44M | 67.60M | 51.88M | 79.74M |
| Book Value | 270.85M | 306.13M | 340.72M | 379.50M | 417.26M | 428.68M | 422.45M | 429.93M | 269.37M | 242.36M | 246.66M | 206.91M |
| Return on Equity | -0.15 | -0.13 | -0.13 | -0.11 | -0.04 | 0.00 | -0.03 | 0.13 | 0.09 | -0.04 | 0.14 | -0.13 |
TRDA News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
Entrada Therapeutics, Inc. (TRDA) Q1 2026 Earnings Call Transcript
Entrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why